Objective:
To review recent advances in the management of diabetic retinopathy (DR) and their implications for clinical practice, particularly in the context of the rising prevalence of diabetes.
Approach:
- Faricimab targets both VEGF-A and Ang-2, showing promise in ongoing trials for DR, which could lead to improved patient outcomes.
- Aflibercept formulations allow for extended dosing intervals, reducing injection frequency and enhancing patient adherence.
- Susvimo offers a continuous delivery system for ranibizumab, improving treatment adherence and potentially reducing the burden of frequent visits.
- TKIs and gene therapy are emerging as innovative approaches to enhance treatment durability, which may significantly impact long-term management.
- Biosimilars are beginning to reshape cost dynamics, providing affordable alternatives that could improve access for patients requiring long-term treatment.
- Ongoing clinical trials mean some therapies are not yet approved for DR, limiting immediate clinical application.
- Adoption of biosimilars is slow due to access and cost considerations, which may hinder their potential benefits in practice.
Key Findings:
Interpretation:
The integration of new therapies and technologies is transforming the management of diabetic retinopathy, offering improved outcomes and reduced treatment burden for patients, which is critical given the rising prevalence of diabetes.
Limitations:
Conclusion:
Advancements in pharmacologic and technological strategies are crucial for improving the management of diabetic retinopathy, with the potential to significantly reduce the burden of vision loss, especially as diabetes prevalence continues to rise.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
